Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma
Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of anlotinib in patients
with stage IV extranodal natural killer/T-cell lymphoma, nasal type.
Phase:
Phase 2
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine